Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.
Citi analyst Geoff Meacham reiterated a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $40.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback